(Q28294793)

English

A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma

scientific article

In more languages
default for all languages
No label defined

No description defined

Statements

A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma (English)
0 references
Paulo M Hoff
0 references
Robert A Wolff
0 references
Karla Bogaard
0 references
Sherry Waldrum
0 references
James L Abbruzzese
0 references
February 2006
0 references
36
0 references
2
0 references
100-3
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit